Program Highlights

Study uses umbilical cord tissue-derived cells for acute ischemic stroke

Enrollment of patients has begun in the first double-blind clinical trial approved by the FDA examining the safety and efficacy of umbilical cord tissue-derived cells for acute ischemic stroke.

Preclinical data on potential benefits of stem cell therapy for stroke

Researchers from The University of Texas Health Science Center at Houston (UTHealth) presented new results at the American Heart Association International Stroke Conference that demonstrated how MultiStem®, a novel stem cell therapy being developed by Athersys, Inc., provided multiple benefits when administered in preclinical models of ischemic stroke.

» read more

Stem Cell Division

Click on the image for a larger view

Click on the image for a larger view

Cellular therapy, including the use of stem cells, is a promising new investigational approach for the treatment of stroke. Extensive animal studies have shown that various stem cells and other types of cells enhance recovery from stroke. Our program is investigating the safety and efficacy of cell therapies for stroke both in animal research and in clinical trials.

Clinical trials available

Autologous Bone Marrow Cells: 1–3 days after stroke
Autologous Bone Marrow Stem Cell Study: 11–20 days after stroke
Allogenic Cell Studies: 1–5 days after stroke

For more information regarding these trials, contact Susan Alderman or Jennifer Garrett.

Program Highlights

Study uses umbilical cord tissue-derived cells for acute ischemic stroke

Preclinical data on potential benefits of stem cell therapy for stroke

Stem Cell Division

Clinical trials available

713.500.7100 main

UT Medical School

Stem Cell

Helpful Links